الفهرس 
Hepatic tumors &Mechanism of hepatocarcinogenesisOnly 14 pages are availabe for public view
 |  | from | 268 |  |  |
| | | from | 268 | | |
Abstract
Hepatocellular carcinoma is the fifth most common malignancy in the world and is one of the most common life threatening malignancies worldwide. HCC accounts for approximately 85% of the primary malignant tumors of the liver. The age adjusted worldwide annual incidence is between 5.5–14.9 people per 100,000 population, resulting in approximately 600,000 to 1,000,000 deaths annually.
Diagnosis of HCC usually occurs in late stages of the disease and usually occurs on routine ultrasonography. The limited treatment options available for HCC emphasize the importance of identifying risk factors for this disease and ultimately developing better stratigies to prevent its development.
The main risk factors for HCC include viral hepatitis infections, metabolic liver diseases, autoimmune liver diseases, aflatoxin exposure, chronic alcohol abuse, NASH, obesity, smoking and bilharziasis.
Hepatic steatosis is a common consequence of HCV infection and has been recently associated with the development of HCC. Steatosis might be contributing to the progression of fibrosis in HCV related disease. Potential mechanisms of this effect include the increased sensitivity of steatotic livers to oxidative stress and cytokine-mediated injury. Hepatic steatosis is more frequently found among HCV genotype 3-infected patients.
HCC prevention include two categories: Primary prevention that is aimed at the prevention of HCC development in patients with chronic liver diseases of different etiologies and secondary prevention that is aimed at preventing the recurrence and / or the development of new HCC.